Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27031631 | 0.86 | HTT (0.43) | NT5EHTTPTGS2PTGS1 | |
| SCHEMBL25198784 | 0.84 | HTT (0.42) | NT5EHTTPTGS2HSD11B1PTGS1 | |
| SCHEMBL25975187 | 0.81 | MC4R (0.45) | HTTPTGS2PTGS1 | |
| SCHEMBL25344707 | 0.81 | USP1 (0.40) | PTGS2HSD11B1 | |
| SCHEMBL25346673 | 0.80 | PTGS2 (0.40) | PTGS2HSD11B1RXRANR1H2NR1H3 | |
| SCHEMBL25343216 | 0.80 | USP1 (0.39) | PTGS2HSD11B1 | |
| SCHEMBL10177256 | 0.80 | NT5E (0.42) | NT5EPTGS2HSD11B1RXRANR1H2 | |
| SCHEMBL30615104 | 0.80 | USP1 (0.39) | PTGS2HSD11B1 | |
| SCHEMBL30615090 | 0.80 | PTGS2 (0.40) | PTGS2HSD11B1RXRANR1H2NR1H3 | |
| SCHEMBL25975478 | 0.80 | EGLN2 (0.38) | PTGS2HSD11B1RXRANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |